Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Feugier, Pierre; Hoof, A. van; Sebban, Catherine; Solal-Céligny, P.; Bouabdallah, Réda; Fermé, Christophe; Berthou, Christian; Lepage, Éric; Tilly, Hervé; Morschhauser, Franck; Gaulard, Philippe; Salles, Gilles; Bosly, André; Gisselbrecht, Christian; Reyes, F; Coiffier, Bertrand

doi:10.1200/jco.2005.09.131

Cited by 1,306 publications

(840 citation statements)

References 20 publications

Supporting

Mentioning

769

Contrasting

Unclassified

Order By: Relevance

“…Results from the GELA study have been recently updated with a 5-year median follow-up and showed a persisting advantage for patients treated with R-CHOP (Table 3) (Coiffier et al, 2002;Feugier et al, 2005). In this study, patients with DLBCL and aged 60-80 years were treated either with eight cycles of CHOP or eight cycles of R-CHOP.…”

Section: Rituximab In Diffuse Large B-cell Lymphomamentioning

confidence: 96%

Rituximab therapy in malignant lymphoma

2007

View full text Add to dashboard Cite

Section: Rituximab In Diffuse Large B-cell Lymphomamentioning

confidence: 96%

Rituximab therapy in malignant lymphoma

2007

View full text Add to dashboard Cite

“…The addition of the anti-CD20 chimeric monoclonal antibody, rituximab, to anthracycline-based chemotherapy has clearly improved survival outcomes in patients with DLBCL in different clinical settings (e.g., early and advanced stage, and older and younger patients) [35][36][37]. The response to combination chemotherapy appears lower in EBV-positive DLBCL than in EBV-negative DLBCL patients.…”

Section: Management Of Ebv-positive Dlbcl Of the Elderlymentioning

confidence: 99%

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

et al. 2016

View full text Add to dashboard Cite

Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid neoplasms. It is a disease typically seen in the elderly and thought to be associated with chronic EBV infection and severe immunosuppression with a component of immunosenescence. Recent research, however, has suggested that EBV‐positive DLBCL can be seen in younger, immunocompetent patients.The diagnosis of EBV‐positive DLBCL of the elderly is made through a careful pathological evaluation. The differential diagnosis includes infectious mononucleosis (specifically in younger patients), lymphomatoid granulomatosis, Hodgkin lymphoma, and gray zone lymphoma, among others. Detection of EBV‐encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined.The International Prognostic Index (IPI), and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor.Patients with EBV‐positive DLBCL should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. It has been suggested, however, that EBV‐positive patients have a worse prognosis than EBV‐negative counterparts in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV‐positive DLBCL. Am. J. Hematol. 91:530–537, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

“…Recently, rituximab in combination with CHOP (R-CHOP) was established as a new standard of care in patients with DLBCL [1,2].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

Mitrović

Ilić

Aurer

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab.Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients.The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.

show abstract

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Abstract: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up. This combination should become the standard for treating these patients.

Cited by 1,306 publications

References 20 publications

Rituximab therapy in malignant lymphoma

Rituximab therapy in malignant lymphoma

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

Contact Info

Product

Resources

About